Skip to content

Categories:

Tag Archives: Emergent BioSolutions

Emergent’s Fuad El-Hibri, an entrepreneur at heart April 2, 2012
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Financial Performance, Food and Drug Administration, Fuad El-Hibri, Healthcare, Trubion Pharmaceuticals, Vaccine, Yale University.
No comments
Emergent BioSolutions Receives NIAID Grant to Support Tuberculosis Vaccine Candidate March 29, 2012
Posted in BacilleCalmette-Guerin, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, TB Vaccine.
No comments
Fuad El-Hibri and the TAKREEM Achievement Awards November 7, 2011
Posted in Arab, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri.
No comments
Fuad El-Hibri Announces Emergent BioSolutionsAward to Supply BioThrax Anthrax Vaccine to U.S. Government October 14, 2011
Posted in BioDefense, BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, U.S. Food and Drug Administration.
No comments
Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference in London September 21, 2011
Posted in Chief executive officer, Emergent BioSolutions, Financial Results, Fuad El-Hibri, Investors.
No comments
Fuad El-Hibri Interviewed by Ricardo Karam September 7, 2011
Posted in Chief executive officer, Emergent BioSolutions, Fuad El-Hibri.
No comments
Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference August 15, 2011
Posted in Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Investors.
No comments
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors June 20, 2011
Posted in Chief executive officer, Emergent BioSolutions, Entrepreneur, Fuad El-Hibri.
No comments
Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation June 10, 2011
Posted in Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, NuThrax, U.S. Food and Drug Administration.
No comments
Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule June 7, 2011
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Food and Drug Administration, Fuad El-Hibri.
No comments
Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference June 1, 2011
Posted in Business, El-Hibri, Financial Performance, Fuad El-Hibri, Healthcare Conference, Investors.
No comments
Emergent BioSolutions Reports Financial Results for First Quarter 2011 May 12, 2011
Posted in BioDefense, BioThrax, Business, Chief executive officer, Chief financial officer, Revenue.
No comments
Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial May 2, 2011
Posted in Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, South Africa.
No comments
Emergent BioSolutions Reports Financial Results for Full Year 2010 April 13, 2011
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Financial Results, Fuad El-Hibri, Trubion Pharmaceuticals.
No comments
Emergent BioSolutions to Present Today at Needham & Company Healthcare Conference April 5, 2011
Posted in Chief executive officer, El-Hibri, Emergent BioSolutions, Fuad Elhibri, Healthcare Conference.
No comments
Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10 February 25, 2011
Posted in Biotechnology and Pharmaceuticals, Chief executive officer, El-Hibri, Emergent BioSolutions, Fuad El-Hibri.
No comments
Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine January 4, 2011
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri.
No comments
Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting December 15, 2010
Posted in American Society of Hematology, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Hematology.
No comments
Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals November 4, 2010
Posted in Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Trubion Pharmaceuticals.
No comments
Emergent BioSolutions to Release Third Quarter 2010 Financial Results and Conduct a Conference Call on November 4, 2010 October 23, 2010
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, NYSE, Vaccine.
No comments
Fuad El-Hibri and The National Health Museum September 30, 2010
Posted in Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, National Health Museum.
No comments
Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine September 20, 2010
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, United States, United States Department of Health and Human Services, Vaccine.
No comments
Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine September 10, 2010
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Vaccine.
No comments
Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars August 30, 2010
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Fuad Elhibri, Scholars Program.
No comments
Emergent BioSolutions to Acquire Trubion Pharmaceuticals August 18, 2010
Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Shareholders, Trubion Pharmaceuticals.
No comments